Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Debt: 2010-2022

Historic Total Debt for Anika Therapeutics (ANIK) over the last 5 years, with Jun 2022 value amounting to $4.3 million.

  • Anika Therapeutics' Total Debt fell 74.42% to $4.3 million in Q2 2022 from the same period last year, while for Jun 2022 it was $17.2 million, marking a year-over-year decrease of 78.41%. This contributed to the annual value of $4.3 million for FY2021, which is 67.04% down from last year.
  • As of Q2 2022, Anika Therapeutics' Total Debt stood at $4.3 million, which was up 0.35% from $4.3 million recorded in Q1 2022.
  • Over the past 5 years, Anika Therapeutics' Total Debt peaked at $50.0 million during Q2 2020, and registered a low of $4.3 million during Q3 2021.
  • For the 3-year period, Anika Therapeutics' Total Debt averaged around $16.3 million, with its median value being $13.1 million (2020).
  • Data for Anika Therapeutics' Total Debt shows a maximum YoY plummeted of 82.80% (in 2021) over the last 5 years.
  • Over the past 3 years, Anika Therapeutics' Total Debt (Quarterly) stood at $13.1 million in 2020, then plummeted by 67.04% to $4.3 million in 2021, then tumbled by 74.42% to $4.3 million in 2022.
  • Its Total Debt was $4.3 million in Q2 2022, compared to $4.3 million in Q1 2022 and $4.3 million in Q4 2021.